Trigeminal neuralgia
Reading File
Searching PubMed
trigeminal neuralgia
Finding Sources
Searching PubMed
trigeminal neuralgia treatment carbamazepine
Reading File
Reading File
Reading File
Reading File
Reading File
I have comprehensive content from all major textbooks. Now let me compile the full, detailed answer.
Trigeminal Neuralgia (Tic Douloureux)
Definition
Trigeminal neuralgia (TN) is a distinct, paroxysmal pain syndrome producing unilateral, severe, electric shock-like facial pain within the distribution of the trigeminal nerve (CN V). It is one of the most painful conditions known in medicine.
Classification (ICHD-3)
| Type | Description |
|---|---|
| Classical TN | Evidence of vascular compression of the trigeminal nerve root (by MRI or surgery), with nerve root atrophy or displacement |
| Secondary TN | Caused by an underlying disease (multiple sclerosis, space-occupying lesion); may include both paroxysmal and continuous pain |
| Idiopathic TN | No causative lesion found and no clear morphological change in the nerve root |
Epidemiology
- Incidence: ~4 per 100,000 individuals
- Onset after age 40 in 90% of patients; peak incidence between 50-70 years
- Slightly more common in women (approximately 1.5:1 female-to-male ratio)
- Incidence increases progressively with age
- Rare familial cases exist, suggesting a possible genetic component
- In younger patients, multiple sclerosis should be considered as a secondary cause
Pathogenesis
The most accepted hypothesis involves neurovascular compression of the trigeminal nerve root entry zone (REZ) at the pons. The key steps are:
- A loop of artery - most commonly the superior cerebellar artery, but also the anterior/posterior inferior cerebellar arteries or superior petrosal vein - contacts or compresses the trigeminal nerve root
- Pulsatile arterial compression, which increases with age-related vessel elongation, causes focal demyelination of primary trigeminal afferents near the REZ
- Demyelinated axons develop focal hyperexcitability, leading to ectopic and repetitive neuronal discharges
- Light mechanical stimuli can then trigger volleys of abnormal firing - explaining the characteristic trigger phenomenon
Pathology studies show vacuolated neurons, segmental demyelination, and vascular changes in gasserian ganglia from TN patients. In secondary TN (e.g., MS plaques, tumors), structural lesions cause pain by a similar mechanism - demyelination or compression at or near the REZ.
Clinical Features
Pain characteristics:
- Episodic, unilateral, brief (seconds, up to 2 minutes)
- Quality: sharp, lancinating, shooting, "electric shock-like"
- Repetitive attacks may blur together; a residual lingering ache may follow prolonged bouts
- Distribution: V2 (cheek/maxillary) and V3 (mandibular) are most common; combined V2+V3 is the most frequent pattern; V1 (ophthalmic) alone is extremely rare
- Attacks during sleep are uncommon but do occur
Triggers (allodynic):
- Light touch to the face (trigger zone most commonly near the nasolabial fold)
- Chewing, teeth brushing, talking
- Cool breeze or air movement across the face
- A refractory period typically follows each triggered attack
After a volley: there is usually a refractory period during which pain cannot be triggered again.
Weight loss and dehydration can result from avoidance of triggers, especially in patients whose pain is triggered by eating.
Physical Findings
- Classical TN: neurological examination is entirely normal - no sensory deficit, motor division intact
- Important red flag: sensory loss or masticatory muscle weakness strongly suggests a secondary cause (trigeminal neuropathy), pointing to a lesion of the gasserian ganglion, main sensory root, or pons
Diagnosis
Diagnostic criteria (ICHD-3 / Goldman-Cecil):
- Paroxysmal attacks of pain lasting 1 second to 2 minutes
- Affecting one or more divisions of the trigeminal nerve
- Pain is intensely sharp, stabbing, or precipitated by a trigger zone
- Stereotypical attacks; no other neurological deficits
Investigations:
- MRI (with high-resolution sequences / MRA): primarily to identify secondary causes (pontine lacunar infarct, demyelinating plaque, meningioma, schwannoma, malignant skull-base infiltration, vascular loops)
- EMG and blink reflex studies are normal in idiopathic/classical TN
- Baseline labs when starting carbamazepine: CBC (monitor for agranulocytosis), LFTs, serum sodium (hyponatremia risk, especially with oxcarbazepine)
Differential diagnosis:
- Trigeminal autonomic cephalalgias (cluster headache, SUNCT - these have autonomic features)
- Atypical facial pain
- Idiopathic stabbing headache
- Tolosa-Hunt syndrome (inflammatory cavernous sinus)
- Dental/TMJ pathology
- Glossopharyngeal neuralgia (pain in throat, ear, posterior tongue, triggered by swallowing)
Treatment
Medical (First-line)
Sodium channel blockers are the drugs of choice:
| Drug | Dose | Notes |
|---|---|---|
| Carbamazepine | Start 50-100 mg, titrate to 600-1200 mg/day in divided doses | First-line; highly favorable response in majority; introduce slowly to avoid vertigo, drowsiness, ataxia in elderly; monitor CBC, LFTs, Na |
| Oxcarbazepine | 300-600 mg/day titrated to 1800 mg/day in 2 divided doses | Better tolerated than carbamazepine; can cause significant hyponatremia |
Once pain is fully controlled, the dose can be gradually tapered to determine if remission has occurred.
Second-line agents (alone or in combination when sodium channel blockers are unhelpful or not tolerated):
- Gabapentin (900-1800 mg) - favorable side-effect profile, sometimes used as initial alternative
- Pregabalin
- Baclofen (50-60 mg)
- Phenytoin (200-300 mg)
- Lamotrigine (100-400 mg)
- Valproate, clonazepam, topiramate
Acute severe attack: IV fosphenytoin (15-20 mg phenytoin sodium equivalents/kg). Topical ophthalmic local anesthetic (proparacaine) to the ipsilateral conjunctival sac can also provide hours to days of relief.
Botulinum toxin type A: Emerging evidence supports its use; a 2024 systematic review (PMID 38558383) found it to be a useful option compared to carbamazepine and oxcarbazepine.
A 2025 meta-analysis (PMID 39995139) confirmed the efficacy and safety profile of both carbamazepine and gabapentin, reinforcing current first- and second-line recommendations.
Surgical (for Medically Refractory Cases)
Failure of sodium channel blockers is an indication for surgical referral. Options:
| Procedure | Mechanism | Notes |
|---|---|---|
| Microvascular decompression (MVD) | Posterior fossa craniotomy; artery freed from nerve, non-absorbable material placed between vessel and nerve root | First definitive option; best for younger, fit patients; may be curative; preserves sensory function; higher procedural risk than ablative options |
| Percutaneous radiofrequency thermocoagulation | Heat ablation of trigeminal sensory root at gasserian ganglion | Up to 93% pain relief; repeatable; procedure of choice in elderly or medically unfit; risk of facial numbness, corneal anesthesia |
| Glycerol rhizotomy | Chemical destruction (glycerol injected into Meckel's cave) | Less invasive; can be repeated |
| Gamma Knife / Stereotactic Radiosurgery (SRS) | Focused radiation to the trigeminal nerve root entry zone | Non-invasive; delayed onset of pain relief; associated with substantial incidence of facial numbness; both LINAC and Gamma Knife used |
| Peripheral nerve block / alcohol injection | Alcohol injected around peripheral branch (mental, infraorbital, supraorbital nerve) | Simple, low morbidity; pain relief lasts 6-18 months; can be repeated 1-2 times before more proximal procedure needed |
MVD vs. SRS: MVD remains the preferred first definitive surgical option because SRS carries a higher risk of post-procedural facial numbness, per Schwartz's Principles of Surgery.
Course and Prognosis
- TN typically follows a relapsing-remitting course over many years
- During flares, attacks may occur dozens of times daily for weeks or months
- Spontaneous remissions can occur at any time and last months to years
- Microvascular decompression is often curative
- Patients whose eating triggers pain are at risk for weight loss and malnutrition - prompt treatment is essential
- Medical management: regular CBC, LFTs, and serum sodium monitoring for the first few months on carbamazepine/oxcarbazepine, then annually
Sources: Bradley and Daroff's Neurology in Clinical Practice, p. 2498-2501 | Goldman-Cecil Medicine, block 53 | Rosen's Emergency Medicine, p. 1352-1358 | Schwartz's Principles of Surgery 11th Ed., p. 1899
Complications of blood transfusion
Finding Sources
Searching PubMed
blood transfusion complications adverse reactions
Finding Sources
Reading File
Searching PubMed
TRALI TACO transfusion related lung injury
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Excellent - I now have very rich content across all major categories. Let me compile the comprehensive answer.
Complications of Blood Transfusion
Transfusion complications are broadly divided into immunological and non-immunological, and further by acute (during or within 24 hours) vs. delayed (days to weeks later), plus complications specific to massive transfusion.
Risk at a Glance (per unit transfused, USA)
| Complication | Risk |
|---|---|
| Febrile non-hemolytic reaction | ~1 : 1,100 |
| Allergic transfusion reaction | ~1 : 1,200 |
| Delayed serologic transfusion reaction | ~1 : 8,000 |
| TACO | ~1 : 9,000 |
| Hypotensive transfusion reaction | ~1 : 32,000 |
| Delayed hemolytic transfusion reaction | ~1 : 32,000 |
| Acute hemolytic transfusion reaction | ~1 : 110,000 |
| TRALI | ~1 : 140,000 |
| TA-GvHD | < 1 : 10,000,000 |
| Post-transfusion purpura | ~1 : 10,000,000 |
(Goldman-Cecil Medicine, Table 162-2)
I. Acute Immunological Complications
1. Acute Hemolytic Transfusion Reaction (AHTR)
Mechanism: Preformed recipient antibodies bind to transfused RBC antigens → antigen-antibody complex activates complement → rapid intravascular hemolysis. The most severe reactions are due to ABO incompatibility (recipient's naturally occurring IgM isoagglutinins). Non-ABO reactions (Rh, Kidd, Duffy, Kell systems) are more common but typically cause extravascular hemolysis and are less severe.
- As little as 10 mL of incompatible blood can trigger a reaction
- ~50% of ABO-incompatible transfusions have no adverse effect; 5% are fatal
- Leading cause: human error - wrong patient identification at sample collection or at bedside
Signs & Symptoms:
- Fever, chills/rigors, anxiety
- Chest pain, abdominal/flank/back pain
- Nausea, vomiting, dyspnea
- Hemoglobinuria (red/brown urine) - often the first sign
- Oliguria/anuria, diffuse bleeding (DIC)
- Under general anesthesia: hemoglobinuria, hypotension, or bleeding diathesis may be the only clues
Complications: Acute renal failure (from hemoglobin precipitation in tubules), DIC
Management:
- Stop the transfusion immediately
- Maintain urine output ≥75-100 mL/h: IV fluids ± mannitol; furosemide if needed
- Alkalinize the urine (protects renal tubules)
- Treat DIC: plasma, cryoprecipitate, platelets, heparin as needed
- Maintain blood pressure (dopamine may be added)
- Return blood unit to blood bank for repeat crossmatch; send patient blood/urine samples
- Monitor: plasma/urine Hb, platelet count, PT, PTT, fibrinogen
2. Febrile Non-Hemolytic Transfusion Reaction (FNHTR)
Most common transfusion reaction - ~1:1,100.
Mechanism:
- RBC components: Donor leukocytes interact with patient white blood cell antibodies
- Platelet components: Leukocyte-derived cytokines accumulate during storage
Diagnosis (criteria): Occurs during or within 4 hours of transfusion; fever >38°C AND ≥1°C rise from pre-transfusion value, OR chills/rigors; no other cause identified. It is a diagnosis of exclusion - AHTR and septic reaction must be ruled out first.
Management:
- Stop transfusion; rule out hemolysis
- Antipyretics (acetaminophen); can restart cautiously if reaction is mild
- Consider blood culture of unit if septic reaction suspected
Prevention: Pre-storage leukoreduction has significantly reduced FNHTR incidence. Premedication (acetaminophen/antihistamines) is only indicated in patients with a prior history of FNHTR - not routinely, as it can mask fever and delay recognition of AHTR.
3. Allergic Transfusion Reaction
Incidence: ~1:1,200; ~8% are severe. Platelets are the most common implicated component.
Mechanism: Recipient IgE antibodies react against proteins in donor plasma. Severe reactions may occur in IgA-deficient patients who have anti-IgA antibodies, triggering anaphylaxis.
Spectrum:
- Mild: urticaria, pruritus, flushing - most common
- Severe/Anaphylactic: bronchospasm, laryngeal edema, hypotension, circulatory shock
Management:
- Stop transfusion; antihistamine (diphenhydramine) for mild reactions; can cautiously restart at slower rate once symptoms improve
- Anaphylaxis: epinephrine + antihistamine + consider hydrocortisone
- IgA-deficient patients: transfuse with IgA-deficient/washed blood products
4. Transfusion-Related Acute Lung Injury (TRALI)
Was the most common cause of transfusion-related mortality (FDA data 2012-2016).
Mechanism: Two-hit model - donor anti-HLA or anti-neutrophil antibodies (present especially in multiparous female donors) activate recipient neutrophils → non-cardiogenic pulmonary edema. All blood components are implicated; FFP is most frequently associated.
Diagnostic criteria:
- No pre-existing acute lung injury before transfusion
- Acute lung injury onset within 6 hours of transfusion
- Hypoxemia (PaO2/FiO2 <300 mmHg or SpO2 <90% on room air)
- Bilateral infiltrates on chest radiograph
- No evidence of circulatory overload / left atrial hypertension
Clinical features: Fever, dyspnea, severe hypoxia, bilateral pulmonary infiltrates - without fluid overload. During anesthesia, a persistent SpO2 drop may be the only sign.
Management: Supportive (respiratory support, often mechanical ventilation); glucocorticoids may be considered. Diuretics are not helpful (distinguishes from TACO). Notify blood bank - donor should be screened for HLA/HNA antibodies.
Prevention: Male-predominant plasma donation policy (reduces HLA-antibody-containing units from multiparous women).
A 2024 systematic review (PMID 38116828) using active surveillance confirmed that TRALI incidence may be higher than passive reporting suggests.
5. Transfusion-Associated Circulatory Overload (TACO)
Incidence: ~1:9,000; likely underreported.
Mechanism: Volume overload → cardiogenic pulmonary edema. Risk factors: elderly, cardiac/renal disease, rapid infusion rate, large volumes.
Features: Dyspnea, hypertension, tachycardia, hypoxia, bilateral infiltrates, elevated BNP/NT-proBNP
Distinction from TRALI:
| Feature | TRALI | TACO |
|---|---|---|
| Mechanism | Non-cardiogenic | Cardiogenic |
| Blood pressure | Often low/normal | Often elevated |
| Response to diuretics | No | Yes |
| BNP | Normal | Elevated |
| Onset | Within 6 h | During/shortly after |
Management: Upright positioning, oxygen, diuretics (furosemide), slow infusion rates in at-risk patients.
6. Hypotensive Transfusion Reaction
- Isolated hypotension (drop ≥30 mmHg systolic) without other features of hemolysis or anaphylaxis
- ~1:32,000; often associated with bradykinin generation especially in patients on ACE inhibitors using bedside leukoreduction filters
- Management: Stop transfusion; supportive
7. Transfusion-Associated Graft-versus-Host Disease (TA-GvHD)
Extremely rare (<1:10,000,000) but highly fatal (>90% mortality).
Mechanism: Donor T lymphocytes engraft in an immunocompromised recipient and attack host tissues (skin, liver, gut, bone marrow).
Risk groups: Severely immunocompromised patients, HLA-matched or directed donations (relative), neonates.
Features: Fever, rash (erythroderma), diarrhea, elevated LFTs, pancytopenia - onset 4-30 days post-transfusion.
Prevention: Irradiation of cellular blood products for at-risk patients. Pathogen reduction technology is an emerging alternative.
8. Post-Transfusion Purpura (PTP)
- Rare (~1:10,000,000); occurs 5-10 days post-transfusion
- Platelet-specific antibodies (most commonly anti-HPA-1a) destroy both donor and recipient platelets
- Presents as sudden severe thrombocytopenia and bleeding
- Management: IVIG (first line), plasmapheresis
II. Delayed Immunological Complications
Delayed Hemolytic Transfusion Reaction (DHTR)
Mechanism: Recipients sensitized by prior transfusion or pregnancy develop alloantibodies that fall to undetectable levels. On re-exposure, an anamnestic (secondary) immune response causes RBC destruction 2-21 days later. Antibodies are most commonly in the Rh and Kidd systems (unlike AHTR which is ABO).
Features: Unexplained fall in Hb 2-21 days post-transfusion, mild jaundice, hemoglobinuria - rarely fatal. In post-op patients, may be mistaken for surgical bleeding.
Diagnosis: Positive direct antiglobulin test (DAT); identify the new alloantibody.
Management: Usually supportive; antigen-negative blood for future transfusions.
III. Infectious Complications
Modern screening has dramatically reduced (but not eliminated) infectious risks:
| Pathogen | Residual Risk per Unit |
|---|---|
| HIV (MP-NAT) | ~1 : 1,800,000 |
| HCV (MP-NAT) | ~1 : 1,600,000 |
| HBV | ~1 : 300,000 - 1,500,000 |
| HTLV | ~1 : 3,300,000 |
| Bacterial contamination | ~1 : 200,000 - 1,000,000 |
| Syphilis | 1 reported case in 50 years (USA) |
| CMV | Risk mitigated by leukoreduction or CMV-negative products |
| Malaria, Chagas disease | Rare in well-screened populations |
Bacterial contamination (septic transfusion reaction) is most common with platelet concentrates (stored at room temperature). Gram-positive organisms (Staphylococcus) predominate. Features: high fever, rigors, hypotension, shock. Management: stop transfusion, blood cultures, broad-spectrum antibiotics.
IV. Complications of Massive Transfusion
Massive transfusion is typically defined as ≥10 units of RBCs in 24 hours.
| Complication | Mechanism | Management |
|---|---|---|
| Dilutional coagulopathy | Dilution of clotting factors and platelets | Balanced resuscitation (RBC:FFP:platelets = 1:1:1); tranexamic acid; cryoprecipitate for low fibrinogen |
| Hypocalcaemia | Citrate (anticoagulant in stored blood) chelates calcium | IV calcium supplementation; monitor ionized calcium |
| Hyperkalaemia | Potassium leaks from stored RBCs during storage | Monitor K+; use fresh blood in neonates and at-risk patients |
| Hypokalaemia | Paradoxical: once cells are metabolically active post-transfusion, K+ re-enters cells | Monitor K+ |
| Hypothermia | Large volumes of cold blood | Blood warmers; active external warming |
| Metabolic acidosis | Lactic acid in stored blood, hypoperfusion | Treat underlying cause |
| Iron overload | Each unit of RBCs contains ~250 mg elemental iron; seen in chronic transfusion-dependent patients (e.g., thalassaemia) | Iron chelation therapy (desferrioxamine, deferasirox) |
Management of coagulopathy in massive transfusion:
- Damage control resuscitation: 1:1:1 ratio of RBC:plasma:platelets
- Tranexamic acid (antifibrinolytic) - given early; most bleeding patients are hyperfibrinolytic
- Cryoprecipitate for low fibrinogen
- Monitor with thromboelastography (TEG/ROTEM) where available
- Avoid crystalloids and colloids where possible
V. Other Complications
- Air embolism: From pressurized administration sets; presents with chest pain, dyspnea, "mill-wheel" murmur; place patient left lateral decubitus/Trendelenburg
- Thrombophlebitis: Local inflammation at IV site
- Citrate toxicity: In massive transfusion (see hypocalcaemia above)
- Immunomodulation (TRIM): Transfusion-related immunomodulation - possible increased susceptibility to infection and tumor recurrence post-transfusion; mechanism not fully defined
Sources: Goldman-Cecil Medicine, Table 162-2/3 | Miller's Anesthesia 10th Ed. | Tietz Textbook of Laboratory Medicine 7th Ed. | Bailey & Love's Short Practice of Surgery 28th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.